Saturday September 19, 2020

Pfizer to buy eczema drugmaker Anacor for $5.2 billion

Pharmaceutical giant makes move in wake of failed Allergan bid

16th May, 2016

Pfizer has agreed to buy Anacor Pharmaceuticals for $5.2 billion – gaining control of an experimental treatment for eczema in its first deal since walking away from a $160 billion takeover of Allergan.

Pfizer will pay $99.25 in cash for each Anacor share, the companies said in a statement today. The transaction, which represents about a 55 per cent premium to Friday’s closing price, is scheduled to be completed in the third quarter and may start adding...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

The state’s National Cyber Security Centre is constantly dealing with suspected attacks and urgently needs more resources

Michael Brennan | 4 days ago

We are far less reliant on the UK as a trading partner now than in previous decades — our focus needs to switch to the many challenges and opportunities of the future

Neale Richmond | 4 days ago

Covid-19 and an economic crisis are exacerbating the trauma of this month’s explosion, writes a Concern worker on the ground

Dom Hunt | 4 weeks ago